SCHEMBL5136497

SCHEMBL5136497

CCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(Cc1ccc(OCc2ccccc2)c(OC)c1)CC1CCCCC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.41
NPC1 O15118 3/20 0.40
RAB9A P51151 2/20 0.40
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
KDM4E B2RXH2 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C9 P11712 1/20 0.38
BLM P54132 1/20 0.38
CSF1R P07333 1/20 0.37
MAPT P10636 2/20 0.36
TP53 P04637 1/20 0.36
HSD17B10 Q99714 2/20 0.36
ALDH1A1 P00352 1/20 0.36
KDM4C Q9H3R0 1/20 0.36
MAPK1 P28482 1/20 0.36
PKM P14618 1/20 0.36
IGF1R P08069 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5136024 0.97 C5AR1 (0.41) C5AR1NPC1RAB9AMEN1KMT2A
SCHEMBL648140 0.94 C5AR1 (0.44) C5AR1MEN1KMT2AMAPTTP53
SCHEMBL648592 0.90 C5AR1 (0.43) C5AR1KMT2AKDM4ECYP3A4MAPT
SCHEMBL5135694 0.89 C5AR1 (0.44) C5AR1KDM4ECYP3A4TP53HSD17B10
SCHEMBL5137096 0.89 C5AR1 (0.42) C5AR1MEN1KMT2AKDM4ECYP3A4
SCHEMBL5137905 0.88 IGF1R (0.43) C5AR1MEN1KMT2AALDH1A1IGF1R
SCHEMBL5134916 0.88 BCHE (0.40) C5AR1MEN1KMT2AKDM4EALDH1A1
SCHEMBL5137523 0.88 MEN1 (0.47) C5AR1NPC1RAB9AMEN1KMT2A
SCHEMBL647832 0.87 AGTR1 (0.41) C5AR1MEN1KMT2AMAPT
SCHEMBL5137356 0.86 MEN1 (0.45) C5AR1MEN1KMT2ACYP3A4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed